A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis (Q46177222)

20 December 2017

title

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis (English)

1 reference

20 December 2017

non-alcoholic steatohepatitis

main subject

biomarker

0 references

steatohepatitis

0 references

1 reference

Zobair M Younossi

1

1 reference

20 December 2017

Sandra Page

2

1 reference

20 December 2017

Nila Rafiq

3

1 reference

20 December 2017

Aybike Birerdinc

4

1 reference

20 December 2017

Maria Stepanova

5

1 reference

20 December 2017

Noreen Hossain

6

1 reference

20 December 2017

Arian Afendy

7

1 reference

20 December 2017

Zahra Younoszai

8

1 reference

20 December 2017

Zachary Goodman

9

1 reference

20 December 2017

Ancha Baranova

10

1 reference

20 December 2017

language of work or name

1 reference

1 April 2011

1 reference

20 December 2017

published in

Obesity Surgery

1 reference

20 December 2017

volume

21

1 reference

20 December 2017

page(s)

431-439

1 reference

20 December 2017

issue

4

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1007/s11695-010-0204-1

exact match

0 references

cites work

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Pathologic assessment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Pathogenesis of non-alcoholic steatohepatitis: human data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Pathogenesis of NASH: animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Evaluation and management of obesity-related nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

The epidemiology of nonalcoholic fatty liver disease: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Role of radiologic modalities in the management of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Protection of estrogens against the progression of chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-010-0204-1

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease

21 January 2018

1 reference

12 December 2020

Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells

1 reference

12 December 2020

Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations

1 reference

12 December 2020

Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance

1 reference

12 December 2020

Comparison of blood tests for liver fibrosis specific or not to NAFLD.

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease

1 reference

12 December 2020

Nonalcoholic fatty liver disease: a practical approach to evaluation and management

1 reference

12 December 2020

The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis

1 reference

12 December 2020

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

1 reference

12 December 2020

10.1007/S11695-010-0204-1

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

20532833

1 reference

20 December 2017